论文部分内容阅读
1.抗人类免疫缺陷病毒(HIV)的新途径过去经美国食品及药品专署(FDA)批准可应用治疗HIV感染的药物仅限于3种针对HIV逆转录酶的核苷类药物。近来在临床试验用的有下列新途径:(1)用HIV重组包膜蛋白(gp160)疫苗作为治疗用。这一重组疫苗多次注射后可在HIV感染者中激发抗体,这种抗体是针对过去未识明的包膜抗原决定簇。在19例原来即对此疫苗有反应的患者中,每4个月免疫一次,18例在经900天治疗后均仍有免疫应答,并可能终身保持反应。另
1. New Approaches to Anti-Human Immunodeficiency Virus (HIV) The drugs approved for the treatment of HIV infection in the past by the U.S. Food and Drug Administration (FDA) are limited to three nucleoside drugs against HIV reverse transcriptase. Recent clinical trials with the following new ways: (1) HIV recombinant envelope protein (gp160) vaccine as a treatment. After multiple injections of this recombinant vaccine, antibodies can be elicited in HIV-infected individuals against an unidentified envelope antigenic determinant in the past. Of the 19 patients who responded to the vaccine, immunized every 4 months, 18 remained immunized after 900 days of treatment and were likely to remain alive for life. another